Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with chronic lymphocytic leukaemia (CLL) confirmed by a pathology test, and who are within seven days of starting a specific type of cancer treatment (a BTK inhibitor, with or without an anti-CD20 antibody, or a BCL2 inhibitor with a drug called Obinutuzumab)
- People who are able to read and speak English or Spanish at roughly an 8th grade level (around 13–14 years of age reading level)
Who may not be able to join:
- People who have dementia or a traumatic brain injury
- People whose leukaemia has spread to the central nervous system (the brain and spinal cord)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sara Tinsley-Vance, PhD, APRN, AOCN, Moffitt Cancer Center
Phone: 813-745-0092
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Health Related Quality of Life (HRQOL); HRQOL predictors; Interactions with treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.